Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 8

CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

April 16, 2025

Caron A. Jacobson, MD, MMSc, Peter Riedell, MD

Experts discuss recent data updates from the TRANSCEND CLL-004 study on the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib, the potential curative role of chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and the future outlook for CAR T in treating R/R CLL.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: CAR-T in Second-Line DLBCL: When and for Whom?

EP. 2: Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024

EP. 3: CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

EP. 4: Guiding Patients Through CAR T: Key Discussion Points

EP. 5: Future Directions for CAR T-Cell Therapy in LBCL: What’s Next?

EP. 6: Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies

EP. 7: Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

Now Viewing

EP. 8: CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

EP. 9: Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

EP. 10: Key Takeaways: CAR T in Real-World Clinical Practice

Video content above is prompted by the following:

There were recent data updates on the combination with liso-cel and ibrutinib from the TRANSCEND CLL-004 study at ASH 2024. Dr Ridell, what were some of the data highlights, and has this data influenced your clinical practice?
In your clinical expertise, is CAR T potentially curative in R/R CLL?
In your opinion, what does the future look like for CAR T in R/R CLL?